{"id":"sparc0912","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"By inhibiting HDAC enzymes, SPARC0912 increases histone acetylation, leading to chromatin remodeling and altered transcription of genes involved in cell cycle arrest, differentiation, and apoptosis. This mechanism is particularly relevant in hematologic malignancies where HDAC inhibition can restore tumor suppressor gene expression and trigger cancer cell death.","oneSentence":"SPARC0912 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histones and non-histone proteins to modulate gene expression and induce anti-tumor effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:35:37.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Peripheral T-cell lymphoma (PTCL)"},{"name":"Cutaneous T-cell lymphoma (CTCL)"}]},"trialDetails":[{"nctId":"NCT00947661","phase":"PHASE3","title":"Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Sun Pharma Advanced Research Company Limited","startDate":"2010-07","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":578}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SPARC0912","genericName":"SPARC0912","companyName":"Sun Pharma Advanced Research Company Limited","companyId":"sun-pharma-advanced-research-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SPARC0912 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histones and non-histone proteins to modulate gene expression and induce anti-tumor effects. Used for Peripheral T-cell lymphoma (PTCL), Cutaneous T-cell lymphoma (CTCL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}